BenevolentAI
regulatory validation a covid treatment now fully approved for use by the novel our technology and work a previously unknown antiviral mechanism published research in rapid the benevolent platform empowered scientists to rapidly formulate a hypothesis in just hours effective shown to reduce mortality from covid in controlled trials barrier trial showed reduces mortality by in patients and by in ventilated or patients led to equity investment from approved the use of to treat covid in may after granting emergency use for in combination with in identified lancet | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
15 of 46
Similar slides by BenevolentAI
See diffirences between slides (animation)
Investor Conference
November 2022
regulatory validation a covid treatment now fully approved for use by the novel our technology and work a previously unknown antiviral mechanism published research in rapid the benevolent platform empowered scientists to rapidly formulate a hypothesis in just hours effective shown to reduce mortality from covid in controlled trials barrier trial showed reduces mortality by in patients and by in ventilated or patients led to equity investment from approved the use of to treat covid in may after granting emergency use for in combination with in identified lancet | BenevolentAI
Investor Day
September 2022
regulatory validation a covid treatment now fully approved for use by the novel our technology and work a previously unknown antiviral mechanism published research in rapid the benevolent platform empowered scientists to rapidly formulate a hypothesis in just hours effective shown to reduce mortality from covid in controlled trials barrier trial showed reduces mortality by in patients and by in ventilated or patients led to equity investment from approved the use of to treat covid in may after granting emergency use for in combination with in identified lancet | BenevolentAI
Related slides by other companies
AN2 Therapeutics
Investor Presentation
February 2025
potential to reduce mortality in patients soc alone | AN2 Therapeutics
AN2 Therapeutics
Investor Presentation
March 2025
potential to reduce mortality in patients soc alone | AN2 Therapeutics
Dare Bioscience
Investor Presentation
February 2023
dare | Dare Bioscience
Dare Bioscience
Investor Presentation
February 2023
advancing products women want the portfolio snapshot | Dare Bioscience
Other recent decks by BenevolentAI
See all presentations (11 decks)
Investor Presentation
September 2024
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights